Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quetiapine fumarate + antidepressant
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy involving **quetiapine fumarate**, an atypical antipsychotic, and an **antidepressant** (the specific agent is not defined; most studies involve SSRIs or SNRIs), used primarily as an **adjunctive treatment for major depressive disorder (MDD) and treatment-resistant depression**. Quetiapine acts as an antagonist at serotonin 5-HT2A, dopamine D2, and several other neurotransmitter receptors, while antidepressants commonly included in such combinations act primarily on serotonin and/or norepinephrine reuptake inhibition. Combination regimens are intended to improve depressive symptoms, quality of sleep, and anxiety, particularly in cases where monotherapy is insufficient. Quetiapine has sedative, anxiolytic, and mood-stabilizing properties, and is also indicated adjunctively in bipolar depression and for symptoms of schizophrenia[1][2][4][5].
- Other names
- SSRI/SNRI and Quetiapine combination therapyAdjunctive Quetiapine with Antidepressants
02
Targets
ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)NET (Norepinephrine Transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)SERT (Sodium-dependent serotonin transporter)ADRA1A (α1A)
Beyond the preview
Go deeper on quetiapine fumarate + antidepressant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quetiapine fumarate + antidepressant.